Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder Case Study Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder Quetiapine is an atypical antipsychotic for treating schizophrenia, bipolar depression, bipolar mania that helps to…Jim Gallagher2021 年 8 月 26 日
Simcyp’s Age-Defining Feature Facilitates Everolimus Dosing in Neonates Case Study Simcyp’s Age-Defining Feature Facilitates Everolimus Dosing in Neonates Everolimus (Afinitor®) was recently approved as adjunctive therapy for tuberous sclerosis complex (TSC)-associated partial seizures…Jim Gallagher2021 年 8 月 26 日
Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Case Study Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Jim Gallagher2021 年 8 月 20 日
Determining Exposures when Transitioning Between Combination Treatments in Cystic Fibrosis: Trikafta Case Study Determining Exposures when Transitioning Between Combination Treatments in Cystic Fibrosis: Trikafta Many cystic fibrosis (CF) patients take several medications at one time to manage symptoms and…Jim Gallagher2021 年 7 月 14 日
Voxelotor for Treating Sickle Cell Disease: Leveraging Dose Prediction Model for DDI Prediction Without Any Clinical Studies Case Study 治疗镰状细胞病的 Voxelotor:无需任何临床研究,利用剂量预测模型进行 DDI 预测 In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…Jim Gallagher2021 年 7 月 14 日
A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development On-Demand Webinar 将 PBPK 模型应用于儿科药物开发的最佳实践框架 Pediatric PBPK models have broad application in the drug development process and are being used…Jim Gallagher2021 年 4 月 20 日
Advancing Pediatric Drug Development Using Simcyp PBPK White Paper 应用 Simcyp™ PBPK 技术推进儿科药物研发 Jim Gallagher2021 年 3 月 4 日
Galderma Achieves FDA Approval of AKLIEF® (trifarotene) Case Study Galderma AKLIEF®(曲法罗汀)获得了 FDA 批准 In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…Certara2020 年 11 月 9 日
The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development Blog The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development 3 key tips to set your pediatric program up for success with the RACE for…Lynne Georgopoulos, RN, MSHS, RAC2020 年 7 月 14 日
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110 Publication Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110 webdev2020 年 1 月 17 日